Clinical Trial Update: Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 blinded efficacy and safety study of CAL02 in addition to standard of care for severe community-acquired bacterial pneumonia; the trial is currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia

Drugs mentioned

• CAL02

Snippet

Sponsor: Eagle Pharmaceuticals, Inc. | Conditions: Pneumonia, Bacterial | Phase 2 | Status: ACTIVE_NOT_RECRUITING